Illumina (ILMN) Stock Forecast & Price Target

Illumina is supported by a durable clinical sequencing franchise, with clinical consumables growing 20% year over year ex-China in 1Q26 and management still framing mid-teens growth as sustainable, underpinned by low market penetration, improving reimbursement, and strong oncology demand from customers like Natera, Guardant Health, Tempus, Caris, and GRAIL. Its economics also appear resilient because pricing actions and volume offsets help preserve margins, while clinical sequencing’s regulatory switching costs and a leading cost structure make competitive threats manageable despite some share loss in academic research. Beyond core sequencing, BioInsight, multiomics launches, and emerging AI-linked data products add incremental growth and help support the case for sustained revenue expansion and margin leverage over time.

Illumina is facing a weak fundamental setup because its growth depends heavily on sequencing instruments, consumables, and services, yet customer economics are being pressured by deflation in per-sample pricing and a shift from NovaSeq 6000 to NovaSeq X that can weigh on core revenue and margins. Despite recent clinical growth acceleration to 17% and then 20%, academic demand remains subdued, pharma and research spending are still cautious, and competitive intensity in nextgen sequencing is the strongest in 15 years, with Roche, MGI, private firms, and long-read players pressuring share. China is another drag, with sales forecast at only ~5% of 2026 revenue versus 10% a few years ago, while a 35x P/E or 20x P/E downside framework implies skepticism that Illumina can sustain sales momentum or expand margins meaningfully.